Summary {#sec0}
=======

Uric acid relates to the occurrence of contrast-induced nephropathy (CIN), but it remains unclear whether it is merely related to traditional risk factors for CIN or plays an independent predictive role. We performed a meta-analysis and a meta-regression analysis of 10 clinical studies. Baseline uric acid levels were significantly higher in those who developed CIN. Statistical analysis revealed that uric acid correlated significantly with age only, but not with other major predictors of CIN, such as diabetes, hypertension, hemoglobin, creatinine, glycemia, cholesterol, and triglycerides. Uric acid seems to have the potential to improve CIN risk stratification.

Introduction {#sec1}
============

Contrast-induced nephropathy (CIN) is one of the most common complications of procedures that require the use of contrast media \[[@cit0001], [@cit0002]\]. Contrast-induced nephropathy occurs in up to 25% of patients undergoing diagnostic and/or therapeutic coronary angiography, depending on the presence of known risk factors, such as chronic kidney disease, diabetes mellitus, high dose of contrast medium, congestive heart failure, and anemia \[[@cit0003], [@cit0004]\]. In recent years, several investigations and some systematic reviews and meta-analyses have shown that hyperuricemia relates to a greater frequency of CIN \[[@cit0005]--[@cit0007]\]. However, no previous investigation has assessed whether serum uric acid plays an independent role in CIN stratification or is merely related to presenting features and procedural characteristics of patients undergoing elective coronary angiography.

Aim {#sec2}
===

The aim of the current study was to perform an updated review and a meta-regression analysis in order to assess whether serum uric acid is associated with CIN or there exists any relationship between serum uric acid and other risk factors for CIN.

Material and methods {#sec3}
====================

Study design {#sec3.1}
------------

This meta-analysis was conducted following current guidelines, including the Cochrane Collaboration and Meta-analysis Of Observational Studies in Epidemiology (MOOSE), and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality of Reporting of Meta-analyses (QUOROM) statement \[[@cit0008]--[@cit0010]\]. All activities were carried out independently by two reviewers (FP and VP). Divergences were solved after consensus.

Data sources {#sec3.2}
------------

We searched PubMed, Embase, and Cochrane databases as well as the National Institutes of Health Clinical Trials Registry ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) up to July 31, 2018 to identify relevant studies. In addition, we searched the presentations at major cardiovascular scientific sessions including meetings of the American College of Cardiology, American Heart Association and European Society of Cardiology. Additional studies were searched in Google Scholar and Scopus. Editorials and reviews from major medical journals published within the last 5 years were also considered for further information on studies of interest. No language restriction was enforced in order to minimize the risk of publication bias. The following combinations of medical subject heading terms and text words were used: "contrast induced acute kidney injury", "contrast induced acute renal failure", "contrast nephropathy", "contrast induced nephropathy", "contrast induced nephrotoxicity", "contrast associated nephropathy", "contrast associated nephrotoxicity", and "radiocontrast induced nephropathy".

Study selection {#sec3.3}
---------------

Retrieved citations were first screened independently by two unblinded investigators (FP and GP) at the title and/or abstract level, with divergences resolved after consensus. Studies were screened in order to identify potentially suitable articles that should be assessed for eligibility as full texts. Notably, a detailed review of study authors, dates, and locations was used to exclude redundancy. Studies with overlapping data were identified, and in cases of apparent serial reporting of a particular patient cohort, only the publication with the largest number of patients was included in the meta-analysis. Only studies published in original articles in peer-reviewed scientific journals were taken into consideration. Studies were then selected according to the following explicit inclusion criteria (all had to be met for inclusion): (i) case series of patients undergoing coronary angiography and/or PCI; (ii) comparison of clinical, laboratory and procedural features between patients with or without post-procedural evidence of CIN; (iii) baseline assessment of uric acid levels.

Data extraction and quality {#sec3.4}
---------------------------

Analysis was performed at the study level, as databases of the individual patients were not obtained. Data from each study were obtained by two independent reviewers (FP and GP) and entered into a structured spreadsheet. Disagreements were resolved by consensus. Dichotomous variables were extracted in absolute numbers and were recalculated when percentages were reported. Continuous variables were extracted and weighted means for the total study population were calculated. The primary endpoint was baseline uric acid levels in patients with or without CIN. Other endpoints were the differences in clinical, laboratory and procedural features between patients with and without CIN, with special emphasis on renal function. Study validity was tested according to recommendations distinguishing several sources of bias. In order to assess the quality of reporting of the studies, the standard Strengthening the Reporting of Observational Studies in Epidemiology checklist (STROBE) was used \[[@cit0011]\]. This checklist includes items assessing the study methodology, study type, study population, sample size, sample collection methods, statistical tests, and presentations.

Data analysis and synthesis {#sec3.5}
---------------------------

All analyses were performed using the Review Manager 5.2.10 software and Comprehensive Meta-analysis Version 3.1. Since heterogeneity of results was expected, the inverse variance method for random effects was used to estimate pooled risk ratios or relative risk for dichotomous variables or mean difference for continuous variables and 95% confidence intervals (CI) \[[@cit0012]\]. We tested the heterogeneity of the included studies with Q statistics and the extent of inconsistency between results with *I* ^2^ statistics. Significant heterogeneity was considered present in the case of *I* ^2^ \> 50% and/or *p* \< 0.10 \[[@cit0013]\]. However, we did not exclude outliers based on heterogeneity since heterogeneity is expected in meta-analyses of observational studies \[[@cit0014]\]. Accordingly, we performed a leave-one-out sensitivity analysis for each parameter in order to evaluate the robustness of the results and the impact of each single study on the summary estimate of effect. Briefly, we recalculated pooled estimates multiple times, using a random-effects model, each time with the removal of a single study from the original group. We also performed a sensitivity analysis stratified by sample size to exclude the possibility of overestimating the role of uric acid due to the inclusion of small studies (defined as those with a sample size \< 500 patients). Presence of publication bias was estimated by the Rucker test (with arcsine transformation), which is best suited for binary outcomes and funnel plot analysis \[[@cit0015], [@cit0016]\]. Meta-regression analysis was conducted to assess whether there was a direct relationship between levels of uric acid and other variables associated with CIN \[[@cit0017]\]. Specifically, we performed a weighted random-effects meta-regression regressing uric acid and CIN against the difference of each variable. Results are reported as beta coefficients and two-sided *p*-values. Statistical significance was set at *p* \< 0.05 (two-tailed).

Results {#sec4}
=======

Search results {#sec4.1}
--------------

From 2,046 initial citations that were retrieved from multiple databases, a total of 78 articles were analyzed as full reports according to predefined selection criteria. After excluding 68 studies because serum uric acid levels in patients with or without CIN were not reported, 10 investigations were finally deemed as eligible for inclusion in our systematic review ([Figure 1](#f0001){ref-type="fig"}) \[[@cit0018]--[@cit0027]\]. A total of 6,705 patients were included in the 10 studies. Selected studies were published between 2010 and 2015, and included series of patients from North America, Europe, and Asia ([Table I](#t0001){ref-type="table"}). All included patients underwent either coronary angiography or percutaneous coronary intervention (PCI). Quality assessment by STROBE checklist revealed moderate to high quality in all studies ([Table II](#t0002){ref-type="table"}).

###### 

List of included studies

  Author       Country   Overall (*n*)   No CIN (*n*)   CIN (*n*)   Coro   PCI   Definition of CIN
  ------------ --------- --------------- -------------- ----------- ------ ----- ----------------------------
  Parkfetrat   Iran      290             245            45          Yes    Yes   SCr \> 50% or \> 0.5 mg/dl
  Okino        China     139             130            9           Yes    Yes   SCr \> 25% or \> 0.5 mg/dl
  Ma           China     69              43             26          Yes    Yes   SCr \> 25% or \> 0.5 mg/dl
  Park         Korea     1247            1,196          51          Yes    Yes   SCr \> 50% or \> 0.5 mg/dl
  Kurtul       Turkey    436             373            63          Yes    Yes   SCr \> 25% or \> 0.5 mg/dl
  Elbasan      Turkey    835             755            80          Yes    Yes   SCr \> 25%
  Saritemur    Turkey    744             651            93          Yes    Yes   SCr \> 25% or \> 0.5 mg/dl
  Ji           China     805             497            68          Yes    Yes   SCr \> 25% or \> 0.5 mg/dl
  Barbieri     Italy     1950            1,699          251         Yes    Yes   SCr \> 25% or \> 0.5 mg/dl
  Karabulut    Poland    430             342            88          Yes    Yes   SCr \> 25% or \> 0.5 mg/dl

###### 

STROBE Statement -- checklist of items that should be included in reports of observational studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                                             Item No.   Recommendation                                                                                                                                                                                                   Score                                           
  -------------------------------------------------------------------------------------------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Title and abstract                                                                                                   1          (*a*) Indicate the study's design with a commonly used term in the title or the abstract                                                                                                                         1       1    1    1    1    1    1    1    1    1

  (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found                1          1                                                                                                                                                                                                                1       1    1    1    1    1    1    1         

  Introduction                                                                                                                                                                                                                                                                                                                                                                                     

   Background/rationale                                                                                                2          Explain the scientific background and rationale for the investigation being reported                                                                                                                             1       1    1    1    1    1    1    1    1    1

   Objectives                                                                                                          3          State specific objectives, including any prespecified hypotheses                                                                                                                                                 1       1    1    1    1    1    1    1    1    1

  Methods                                                                                                                                                                                                                                                                                                                                                                                          

   Study design                                                                                                        4          Present key elements of study design early in the paper                                                                                                                                                          1       1    0    1    0    1    0    1    1    1

   Setting                                                                                                             5          Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection                                                                                  1       1    1    1    1    1    1    1    1    1

   Participants                                                                                                        6          (*a*) *Cohort study* -- Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up\                                                                  1       1    1    1    1    1    1    1    1    1
                                                                                                                                  *Case-control study* -- Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls\                                                                         
                                                                                                                                  *Cross-sectional study --* Give the eligibility criteria, and the sources and methods of selection of participants                                                                                                                                               

  (*b*) *Cohort study --* For matched studies, give matching criteria and number of exposed and unexposed\             1          0                                                                                                                                                                                                                0       0    1    1    0    1    0    0         
  *Case-control study --* For matched studies, give matching criteria and the number of controls per case                                                                                                                                                                                                                                                                                          

   Variables                                                                                                           7          Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable                                                                         1       1    0    1    1    1    1    1    0    0

   Data sources/measurement                                                                                            8          For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group                             1       1    1    1    1    1    1    1    1    1

   Bias                                                                                                                9          Describe any efforts to address potential sources of bias                                                                                                                                                        1       1    0    1    0    1    0    1    0    0

   Study size                                                                                                          10         Explain how the study size was arrived at                                                                                                                                                                        0       0    0    0    0    0    0    0    0    0

   Quantitative variables                                                                                              11         Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why                                                                                     1       1    0    1    1    1    1    1    1    1

   Statistical methods                                                                                                 12         (*a*) Describe all statistical methods, including those used to control for confounding                                                                                                                          1       1    1    1    1    1    1    1    1    1

  (*b*) Describe any methods used to examine subgroups and interactions                                                1          1                                                                                                                                                                                                                1       1    1    1    1    1    1    1         

  (*c*) Explain how missing data were addressed                                                                        1          1                                                                                                                                                                                                                1       1    1    1    1    1    1    1         

  (*d*) *Cohort study --* If applicable, explain how loss to follow-up was addressed\                                  0          0                                                                                                                                                                                                                0       0    1    0    1    0    0    0         
  *Case-control study --* If applicable, explain how matching of cases and controls was addressed\                                                                                                                                                                                                                                                                                                 
  *Cross-sectional study --* If applicable, describe analytical methods taking account of sampling strategy                                                                                                                                                                                                                                                                                        

  (*e*) Describe any sensitivity analyses                                                                              1          1                                                                                                                                                                                                                1       1    1    1    1    0    0    1         

  Results                                                                                                                                                                                                                                                                                                                                                                                          

   Participants                                                                                                        13\*       (*a*) Report numbers of individuals at each stage of study, eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed             1       1    1    1    1    1    1    1    1    1

  (*b*) Give reasons for non-participation at each stage                                                               1          1                                                                                                                                                                                                                0       0    0    0    0    0    0    0         

  (*c*) Consider use of a flow diagram                                                                                 1          0                                                                                                                                                                                                                1       1    1    0    1    0    0    1         

   Descriptive data                                                                                                    14\*       (*a*) Give characteristics of study participants (eg. demographic, clinical, social) and information on exposures and potential confounders                                                                      1       1    0    1    1    1    1    1    0    1

  (*b*) Indicate number of participants with missing data for each variable of interest                                1          1                                                                                                                                                                                                                1       1    1    1    1    1    1    1         

  (*c*) *Cohort study --* Summarise follow-up time (eg. average and total amount)                                      --         --                                                                                                                                                                                                               --      --   --   0    --   --   --   --        

   Outcome data                                                                                                        15\*       *Cohort study --* Report numbers of outcome events or summary measures over time                                                                                                                                 --      --   --   --   --   1    --   --   --   --

  *Case-control study --* Report numbers in each exposure category, or summary measures of exposure                    1          --                                                                                                                                                                                                               1       1    1    --   --   1    1    1         

  *Cross-sectional study --* Report numbers of outcome events or summary measures                                      --         1                                                                                                                                                                                                                --      --   --   --   1    --   --   --        

   Main results                                                                                                        16         (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   1       1    0    1    0    1    0    0    0    0

  (*b*) Report category boundaries when continuous variables were categorized                                          0          0                                                                                                                                                                                                                0       0    0    0    0    1    0    0         

  (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   0          0                                                                                                                                                                                                                0       0    0    1    0    0    0    0         

   Other analyses                                                                                                      17         Report other analyses done, eg analyses of subgroups and interactions, and sensitivity analyses                                                                                                                  1       1    1    1    1    1    1    1    1    1

  Discussion                                                                                                                                                                                                                                                                                                                                                                                       

   Key results                                                                                                         18         Summarise key results with reference to study objectives                                                                                                                                                         1       1    1    1    1    1    1    1    1    1

   Limitations                                                                                                         19         Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias                                                       1       1    0    0    0    1    0    0    0    0

   Interpretation                                                                                                      20         Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                       1       1    1    1    1    1    1    1    1    1

   Generalisability                                                                                                    21         Discuss the generalisability (external validity) of the study results                                                                                                                                            1       1    1    1    1    1    1    1    1    1

  Other information                                                                                                                                                                                                                                                                                                                                                                                

   Funding                                                                                                             22         Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based                                                    0       0    0    0    0    1    0    1    0    0

  Total scores                                                                                                         28         26                                                                                                                                                                                                               19      25   24   28   23   25   19   24        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![PRISMA diagram of study selection. The flow diagram demonstrates the study selection process in the systematic review and meta-analysis](PWKI-14-34233-g001){#f0001}

Definition of CIN {#sec4.2}
-----------------

CIN was defined variously in the studies. Most studies described CIN as an increase in serum creatinine levels of more than 25% or 0.5 mg/dl above the baseline 48--72 h following intravascular contrast medium administration \[[@cit0019], [@cit0020], [@cit0022], [@cit0024]--[@cit0027]\]. CIN was defined according to the RIFLE criteria by Pakfetrat *et al.* \[[@cit0018]\] as an increase in serum creatinine of ≥ 0.5 mg/dl or ≥ 50% over baseline within 7 days by Park *et al.* \[[@cit0021]\], and as an increase ≥ 25% in creatinine by Elbasan *et al.* \[[@cit0023]\].

Primary end-point {#sec4.3}
-----------------

CIN occurred in 774 of the 6,705 (11.5%) patients. Frequency of CIN ranged between 4.1% and 37.7%. Baseline uric acid levels were significantly higher in those who developed CIN 6.51 (95% CI: 6.23--6.78) vs. 5.67 (95% CI: 5.25--6.09) mg/dl; mean difference: 0.88, 95% CI 0.55--1.22, *p* \< 0.00001; *I* ^2^ = 83%, *p* \< 0.00001) ([Table III](#t0003){ref-type="table"}; [Figure 2](#f0002){ref-type="fig"}).

###### 

Baseline presenting features of overall population

  Author       Uric acid \[mg/dl\]       Age \[years\]             Men                 Diabetes            Smoking           Hypertension    Hyperlipidemia                                                                                                          
  ------------ ------------------------- ------------------------- ------------------- ------------------- ----------------- --------------- ----------------- --------------- ----------------- --------------- ----------------- --------------- ----------------- ---------------
  Parkfetrat   6.20 (1.60)               6.10 (2.00)               58 (12)             58 (11)             159 (88)          21 (12)         NA                NA              NA                NA              NA                NA              NA                NA
  Okino        6.60 (1.60)               7.30 (2.70)               69 (8)              71 (11)             111 (93)          8 (89)          65 (50)           5 (56)          NA                NA              100 (77)          6 (67)          NA                NA
  Ma           4.81 (1.15)               6.75 (1.99)               67 (9)              72 (8)              NA                NA              8 (19)            7 (27)          NA                NA              23 (54)           21 (81)         NA                NA
  Park         5.12 (1.54)               6.51 (2.23)               64 (12)             69 (10)             NA                NA              378 (32)          34 (67)         NA                NA              NA                NA              NA                NA
  Kurtul       5.49 (1.53)               6.53 (1.76)               61 (12)             72 (13)             241 (65)          39 (62)         119 (32)          23 (37)         176 (47)          10 (16)         161 (43)          35 (56)         110 (30)          11 (18)
  Elbasan      5.10 (0.90)               6.20 (0.9)                58 (12)             65 (13)             564 (75)          51 (64)         221 (29)          37 (46)         298 (39)          31 (39)         290 (38)          30 (38)         195 (26)          22 (28)
  Saritemur    4.89 (1.32)               6.09 (2.01)               55 (12)             64 (11)             475 (73)          55 (59)         135 (21)          39 (42)         361 (56)          51 (55)         265 (41)          57 (61)         242 (37)          37 (40)
  Ji           6.02 (1.75)               6.78 (1.96)               66 (11)             73 (10)             232 (47)          38 (56)         132 (27)          26 (38)         NA                NA              262 (53)          52 (77)         NA                NA
  Barbieri     6.35 (1.79)               6.60 (1.81)               72 (NA)             75 (NA)             1134 (67)         189 (75)        632 (37)          90 (36)         263 (15)          26 (10)         1287 (76)         189 (75)        928 (55)          135 (54)
  Karabulut    6.08 (2.10)               6.83 (1.9)                64 (13)             66 (10)             208 (61)          62 (71)         129 (38)          42 (48)         248 (73)          64 (73)         248 (74)          65 (76)         171 (50)          40 (47)
  Overall      5.67 95% CI: 5.25--6.09   6.51 95% CI: 6.23--6.78   63 95% CI: 59--67   69 95% CI: 64--72   3124/4510 (69%)   463/686 (67%)   1819/5686 (32%)   303/729 (42%)   1346/3638 (37%)   182/564 (32%)   2636/4490 (59%)   455/678 (67%)   1646/3638 (45%)   245/564 (43%)
  *P*-value    \< 0.00001                \< 0.00001                0.970               0.002               0.105             0.03            0.864                                                                                                                   

CIN -- contrast-induced nephropathy, LV -- left ventricular.

![Forest plot of risk ratios for contrast-induced nephropathy according to uric acid. Markers represent point estimates of risk ratios, marker size represents study weight. Horizontal bars indicate 95% confidence intervals](PWKI-14-34233-g002){#f0002}

Factors associated with CIN {#sec4.4}
---------------------------

Comparison of clinical features at referral showed that patients who experienced CIN were significantly older (69 (95% CI: 64--72) vs. 63 (95% CI: 59--67) years; mean difference: 5.25, 95% CI: 3.19-7.32, *p* \< 0.00001; *I* ^2^ = 81%, *p* \< 0.00001), more often had diabetes (42% vs. 32%; risk ratio: 0.70, 95% CI: 0.56--0.88, *p* = 0.002; *I* ^2^ = 81%, *p* \< 0.00001) and hypertension (67% vs. 59%; risk ratio: 0.84, 95% CI: 0.72--0.98, *p* = 0.03; *I* ^2^ = 81%, *p* \< 0.00001), with no difference in prevalence of smoking and hyperlipidemia ([Table III](#t0003){ref-type="table"}; [Figure 3](#f0003){ref-type="fig"}). With respect to laboratory findings at baseline, patients who developed CIN had lower hemoglobin (12.5 (95% CI: 12.1--12.9) vs. 13.6 (95% CI: 13.2--13.9) mg/dl; mean difference: 1.02, 95% CI: 0.61--1.42, *p* \< 0.00001; *I* ^2^ = 71%, *p* = 0.0002) and higher levels of baseline creatinine (1.27 (95% CI: 1.07--1.43) vs. 1.01 (95% CI: 0.86--1.16) mg/dl; mean difference: 0.22, 95% CI: 0.11--0.32, *p* \< 0.0001; *I* ^2^ = 94%, *p* = 0.00001), but had similar levels of glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride ([Table IV](#t0004){ref-type="table"}; [Figure 3](#f0003){ref-type="fig"}). Also, they showed a lower ejection fraction (45% (95% CI: 42--47) vs. 50% (95% CI: 46--53); mean difference: 4.89, 95% CI: 2.77--7.01, *p* \< 0.00001; *I* ^2^ = 71%, *p* = 0.002) ([Table V](#t0005){ref-type="table"}; [Figure 4](#f0004){ref-type="fig"}).

###### 

Laboratory findings at baseline

  Author       Hemoglobin \[g/l\]              Glycemia \[mg/dl\]              Total cholesterol \[mg/dl\]   LDL cholesterol \[mg/dl\]   HDL cholesterol \[mg/dl\]   Triglyceride \[mg/dl\]                                                                                                                                        
  ------------ ------------------------------- ------------------------------- ----------------------------- --------------------------- --------------------------- --------------------------- -------------------------- -------------------------- ----------------------- ----------------------- --------------------------- ---------------------------
  Parkfetrat   NA                              NA                              125 (63)                      131 (54)                    186 (48)                    189 (30)                    111 (37)                   110 (25)                   39 (11)                 42 (14)                 184 (106)                   155 (79)
  Okino        NA                              NA                              NA                            NA                          NA                          NA                          NA                         NA                         NA                      NA                      NA                          NA
  Ma           NA                              NA                              107 (99--136)                 125 (106--143)              195 (40)                    203 (50)                    NA                         NA                         NA                      NA                      NA                          NA
  Park         13.5 (1.9)                      11.9 (2.1)                      118 (39)                      145 (73)                    NA                          NA                          NA                         NA                         NA                      NA                      NA                          NA
  Kurtul       14.1 (1.9)                      12.7 (2.1)                      158 (87)                      158 (78)                    191 (49)                    176 (51)                    121 (42)                   106 (40)                   41 (10)                 42 (11)                 131 (35--815)               112 (39--624)
  Elbasan      13.6 (1.9)                      12.2 (2.2)                      146 (79)                      159 (86)                    190 (46)                    191 (40)                    122 (37)                   122 (37)                   38 (9)                  39 (12)                 148 (118)                   153 (87)
  Saritemur    13.6 (1.8)                      12.9 (2.2)                      NA                            NA                          NA                          NA                          113 (36)                   116 (42)                   39 (12)                 41 (12)                 139 (93)                    123 (64)
  Ji           13.3 (1.8)                      12.6 (2.2)                      NA                            NA                          158 (43)                    158 (50)                    95 (37)                    94 (42)                    NA                      NA                      180 (12--483)               158 (20--189)
  Barbieri     13.2 (NA)                       12.7 (NA)                       127 (NA)                      134 (NA)                    159 (NA)                    159 (NA)                    91 (NA)                    92 (NA)                    41 (NA)                 42 (NA)                 140 (NA)                    137 (NA)
  Karabulut    NA                              NA                              NA                            NA                          NA                          NA                          NA                         NA                         NA                      NA                      NA                          NA
  Overall      13.6 (0.3) 95% CI: 13.2--13.9   12.5 (0.4) 95% CI: 12.1--12.9   130 (19) 95% CI: 110--149     142 (14) 95% CI: 127--157   180 (17) 95% CI: 162--197   179 (18) 95% CI: 160--198   108 (13) 95% CI: 95--122   106 (12) 95% CI: 94--119   40 (2) 95% CI: 37--41   41 (2) 95% CI: 39--43   153 (22) 95% CI: 130--177   139 (19) 95% CI: 119--159
  *P*-value    \< 0.00001                      0.239                           0.923                         0.788                       0.092                       0.271                                                                                                                                                         

CIN -- contrast-induced nephropathy, HDL -- high-density lipoprotein, LDL -- low-density lipoprotein.

###### 

Pre- and post-procedural findings

  Author       Contrast media \[ml\]   Baseline eGFR          Baseline creatinine \[mg/dl\]   Post-creatinine \[mg/dl\]   LV ejection fraction (%)                                                                                                     
  ------------ ----------------------- ---------------------- ------------------------------- --------------------------- -------------------------- ------------------------- ------------------------- ------------------------- ------------------- -------------------
  Parkfetrat   62 (45)                 84 (73)                82 (36)                         67 (16)                     0.90 (0.30)                1.10 (0.20)               NA                        NA                        49 (13)             43 (17)
  Okino        177 (131)               148 (74)               40 (13)                         32 (11)                     1.43 (0.60)                1.67 (0.43)               NA                        NA                        NA                  NA
  Ma           160 (46)                181 (53)               NA                              NA                          NA                         NA                        NA                        NA                        56 (10)             47 (10)
  Park         306 (132)               359 (159)              86 (33)                         45 (26)                     0.81 (0.26)                1.52 (0.71)               NA                        NA                        55 (13)             47 (14)
  Kurtul       NA                      NA                     72 (20)                         50 (18)                     1.06 (0.27)                1.37 (0.38)               NA                        NA                        47 (10)             40 (10)
  Elbasan      197 (79)                253 (124)              NA                              NA                          0.91 (0.22)                0.96 (0.26)               0.97 (0.23)               2.29 (1.40)               46 (10)             44 (8)
  Saritemur    256 (64)                286 (72)               90 (23)                         70 (23)                     0.86 (0.20)                1.03 (0.40)               0.93 (NA)                 1.71 (NA)                 48 (8)              44 (9)
  Ji           NA                      NA                     65 (25)                         50 (30)                     0.94 (0.37)                1.36 (0.79)               NA                        NA                        NA                  NA
  Barbieri     217 (NA)                291 (NA)               NA                              NA                          1.18 (NA)                  1.17 (NA)                 1.20 (NA)                 1.78 (NA)                 NA                  NA
  Karabulut    NA                      NA                     69 (21)                         64 (23)                     1.05 (0.27)                1.13 (0.25)               1.07 (0.27)               1.69 (0.70)               48 (15)             47 (14)
  Overall      196 95% CI: 125--267    208 95% CI: 140--316   72 95% CI: 56--87               54 95% CI: 41--66           1.01 95% CI: 0.86--1.16    1.27 95% CI: 1.07--1.43   1.04 95% CI: 0.85--1.23   1.86 95% CI: 1.41--2.31   50 95% CI: 46--53   45 95% CI: 42--47
  *P*-value    0.800                   0.053                  \< 0.0001                       0.043                       \< 0.00001                                                                                                                   

CIN -- contrast-induced nephropathy, CKD -- chronic kidney disease, eGFR -- estimated glomerular filtration rate.

![Forest plot of risk ratios for contrast-induced nephropathy according to age (**A**), diabetes (**B**) and hypertension (**C**). Markers represent point estimates of risk ratios, marker size represents study weight. Horizontal bars indicate 95% confidence intervals](PWKI-14-34233-g003){#f0003}

![Forest plot of risk ratios for contrast-induced nephropathy according to hemoglobin (**A**), creatinine (**B**) and ejection fraction (**C**). Markers represent point estimates of risk ratios, marker size represents study weight. Horizontal bars indicate 95% confidence intervals](PWKI-14-34233-g004){#f0004}

Meta-regression analysis {#sec4.5}
------------------------

Meta-regression ([Table VI](#t0006){ref-type="table"}) revealed that uric acid, apart from a relationship with age (*r* = --0.75, *p* = 0.02), was not associated with major risk factors for CIN, i.e. diabetes, hypertension, ejection fraction, hemoglobin and baseline creatinine ([Figures 5](#f0005){ref-type="fig"} and [6](#f0006){ref-type="fig"}).

###### 

Meta-regression weighted by total sample size of studies

  Parameter           β        95% CI         *P*-value
  ------------------- -------- -------------- -----------
  Age                 0.13     0.01--0.26     0.03
  Hemoglobin          --1.06   --2.10--0.01   0.06
  Diabetes            0.04     --0.01--0.08   0.07
  Hypertension        0.02     --0.03--0.07   0.40
  Creatinine          0.71     --1.78--3.20   0.58
  Ejection fraction   --0.06   --0.28--0.16   0.62

![Meta-regression of the effects of age, hypertension and diabetes on baseline uric acid levels. Each circle size represents a study highlighted by its weight in the analysis](PWKI-14-34233-g005){#f0005}

![Meta-regression of the effects of creatinine, left ventricular ejection fraction and haemoglobin on baseline uric acid levels. Each circle size represents a study highlighted by its weight in the analysis](PWKI-14-34233-g006){#f0006}

Sensitivity analysis and publication bias {#sec4.6}
-----------------------------------------

The leave-one-out analysis showed that the pooled results were not influenced by any single trial. In addition, excluding studies with large (\> 500 patients) or small (\< 500 patients) sample sizes did not change results of the meta-analyses. Rucker's test did not suggest publication bias (*p* = 0.77 for CIN). Funnel plot analysis showed no asymmetry suggesting a significant risk of publication bias, and that the end-points did not depend on the size of the studies ([Figure 7](#f0007){ref-type="fig"}).

![Funnel plot for the occurrence of CIN. The analysis showed no asymmetry suggesting a significant risk of publication bias, and that results did not depend on the size of the studies](PWKI-14-34233-g007){#f0007}

Discussion {#sec5}
==========

Serum uric acid is an underestimated and under-reported parameter in studies dealing with cardiac angiography and interventional procedures. Our study is the first meta-regression on this topic, showing that uric acid does not correlate with major predictors of CIN, with the exception of age, thus indicating that it might constitute a novel independent predictor to be included in CIN risk stratification.

Serum uric acid is the final product of purine metabolism, and uric acid levels depend on many factors, including diet, drug therapy, presence of kidney disease, increased purine turnover, etc. Hyperuricemia is associated with urate deposition, leading to gout arthritis and kidney stones \[[@cit0028]\]. Uric acid may also have a role in acute renal failure. Indeed, several studies have suggested a significant association between hyperuricemia and the development and progression of kidney disease and renal function impairment \[[@cit0029]--[@cit0031]\]. Uric acid can also impair endothelial function, as it inactivates nitric oxide, i.e. endothelium-derived relaxing factor, and inhibits release of nitric oxide from endothelial cells \[[@cit0032]\]. The relationship between hyperuricemia and renal failure may be helpful for understanding the association between uric acid and CIN. However, to date, limited information is available on the effects of contrast media on uric acid metabolism. Two pioneer investigations in the 1970s showed that contrast agents have a uricosuric effect with enhanced renal tubular secretion of uric acid and a possible nephrotoxic effect \[[@cit0033], [@cit0034]\]. In addition, uric acid is associated with other factors that play a role in the pathogenesis of CIN, such as enhanced synthesis of reactive oxygen species, activation of the renin--angiotensin--aldosterone system, an increase in endothelin-1, and inhibition of the nitric oxide system \[[@cit0035]\].

Various patient- and procedure-related risk factors may contribute to CIN. Pre-existing renal insufficiency and diabetes mellitus are the two main patient-related risk factors. In a retrospective review of 938 patients with stable renal insufficiency, the overall incidence of CIN was 6.1%, while the incidence was 4.4%, 10.5% and 10.0% in patients whose eGFR was 45--60, 30--45 and ≤ 30 ml/min, respectively \[[@cit0036]\]. In the present study, baseline factors significantly associated with CIN included age, creatinine, lower hemoglobin, lower ejection fraction, diabetes and hypertension. It may be hypothesized that uric acid might be a marker for the presence of one or more of these well-known risk factors. However, our meta-regression analysis showed only a moderate significant association between uric acid and age, as expected, while other risk factors, including baseline creatinine, diabetes and hypertension, did not show any relationship with uric acid. These results suggest an independent association between uric acid and CIN, not mediated by other risk factors. It is worth noting the lack of association between uric acid and baseline levels of creatinine, which is the most important single risk factor for CIN \[[@cit0001]\]. Measuring serum uric acid levels before PCI might be a useful method for assessing the risk of developing CIN and short-term clinical outcomes. The difference in uric acid levels between patients with or without CIN was 0.88 mg/dl, suggesting that even a moderate increase in uric acid levels can be of clinical relevance in this setting. Noteworthy, our findings are in agreement with previous work by Shacham *et al.*, who performed a retrospective analysis of 1,372 consecutive patients with acute myocardial infarction and found that uric acid was an independent predictor of CIN \[[@cit0037]\]. Interestingly, these authors noted that for every 1-mg/dl increase in the uric acid concentration, the adjusted risk for CIN increased by 46% \[[@cit0037]\].

There are some intrinsic limitations of this study as a result of the study design. Major limitations include the case-control design and the relatively small number of studies included in the meta-analysis, which might affect the main results and the results of the meta-regression analysis. Another limitation is the high heterogeneity among the studies. Indeed, studies selected for this meta-analysis differ in multiple aspects (i.e. sample size, definition or frequency of CIN, etc). However, in order to evaluate the stability of the results, we performed a 'leave-one-out' sensitivity analysis and were able to show that omission of each study did not change the overall results. We acknowledge the fact that assessment of serum uric acid is affected by the hydration status. Also, the results of the present study should not lead to disregarding the well-recognized role of diabetes, hypertension and renal function, which have been previously demonstrated to be major predictors of CIN. Our review focused only on studies in which contrast was administered for a coronary procedure; therefore, the risk models reviewed might not be applied to other procedures, such as intravenous contrast-enhanced computed tomography, computed tomography angiography, and non-coronary angiography. Publication bias always remains a concern because this investigation could analyze only published data, although funnel plot analysis did not show any evidence of publication bias. A possible drawback lies in the study-level setting, thus lacking the precision and flexibility of a patient-level work, which would have enabled more detailed analyses. Although individual patient data would have provided more detailed information, patient-level and study-level meta-analyses are often in agreement, and thus our findings should be consistent with future prospective studies in individual patients. Although the case control design of selected studies does not allow uric acid to be defined as an independent risk factor, our meta-regression analysis does not suggest a correlation of uric acid with other risk factors, with the exception of age.

Conclusions {#sec6}
===========

This large study-level meta-analysis and meta-regression indicates that uric acid is significantly associated with CIN. Uric acid correlated significantly with age only, but not with other major predictors of CIN. These results should be considered hypothesis-generating findings that may warrant further investigation to verify the potential role of uric acid to improve CIN risk stratification.

Conflict of interest
====================

The authors declare no conflict of interest.
